Safety and performance of the ACURATE TATM system have been tested in 40 patients enrolled in the First-in-Men study and in 50 patients enrolled in the Pilot study, also called ‘TA90 cohort’ [3, 5]. To determine whether the outcomes obtained in controlled study settings can be translated to clinical routine, the first 250 commercially treated patients were enrolled in the ‘Symetis ACURATE TATMValve Implantation’ registry (SAVI-1) [5, 6]. One year later, SAVI-2 was started to continue to collect and monitor ongoing safety and efficacy data on the commercial use of the product. This report combines the 1-year outcomes of both registries.